Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trellus HealthFRA:85Q 5-Year RORE % is 22.37 as of Jun. 2025. The stock has 2 warning signs investors should review. Among 511 Healthcare Providers & Services companies, Trellus Health ranks better than 76.32% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Trellus Health's 5-Year RORE % for the quarter that ended in Jun. 2025 was 22.37%.
The industry rank for Trellus Health's 5-Year RORE % or its related term are showing as below:
FRA:85Q's 5-Year RORE % is ranked better than 76.32% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 2.24
vs FRA:85Q: 22.37
Trellus Health (FRA:85Q) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Trellus Health 5-Year RORE % Related Terms
Trellus Health 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Trellus Health's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:85Q vs VEEV, BTSG, TEM: 5-Year RORE % Comparison
For the Health Information Services subindustry, Trellus Health's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trellus Health 5-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Trellus Health's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Trellus Health's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 5-year before.
Trellus Health (FRA:85Q) has a 5-Year RORE % of 22.37 as of Jun. 2025. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Trellus Health and its competitors. According to the industry distribution chart, Trellus Health ranks #121 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 23.7%.
Is Trellus Health's 5-Year RORE % too high?
Trellus Health's current 5-Year RORE % is 22.37. The Healthcare Providers & Services industry median 5-Year RORE % is 2.24. Trellus Health's value of 22.37 is 898.7% above this industry median. Based on the distribution chart, Trellus Health ranks #121 out of 511 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Trellus Health's 5-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Trellus Health ranks #121 out of 511 companies for 5-Year RORE %. This places Trellus Health in the top 24% of its industry — outperforming the majority of peers. The industry median 5-Year RORE % is 2.24. Trellus Health's value of 22.37 is 898.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Healthcare Providers & Services company?
The median 5-Year RORE % among Healthcare Providers & Services companies is 2.24, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trellus Health's current 5-Year RORE % of 22.37 is 898.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Trellus Health and its competitors. For the Healthcare Providers & Services industry, the median 5-Year RORE % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trellus Health's current 5-Year RORE % is 22.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trellus Health stock overvalued right now?
Trellus Health (FRA:85Q) has a current 5-Year RORE % of 22.37. The current 5-Year RORE % is 22.37 and 898.7% above the Healthcare Providers & Services industry median of 2.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Trellus Health (FRA:85Q), the current 5-Year RORE % is 22.37 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:85Q has been successfully added to your 
